CXCR4是一種含七個跨膜結(jié)構(gòu)域的G蛋白偶聯(lián)受體（GPCR），是基質(zhì)衍生因子-1（SDF-1/CXCL12）的特異性CXC趨化因子受體?CXCR4最初被發(fā)現(xiàn)的身份是HIV入侵CD4+ T細(xì)胞的共受體之一，阻斷CXCR4有望成為HIV治療的新策略?CXCR4信號通路在造血干細(xì)胞的遷移?增殖和靜息及其在骨髓中的滯留中發(fā)揮重要作用，并介導(dǎo)B細(xì)胞CD20的上調(diào)?CXCR4在23種以上的腫瘤中高表達(dá)（包括乳腺癌?卵巢癌?黑色素瘤和前列腺癌），而在正常組織中表達(dá)極低或不表達(dá),其表達(dá)與腫瘤的存活?生長和向高SDF-1/CXCL12表達(dá)組織（如肺?肝?骨髓）的轉(zhuǎn)移密切相關(guān)?

ProSci的CXCR4多克隆抗體（貨號1009）是腫瘤微環(huán)境與免疫研究領(lǐng)域的理想工具?該抗體以人CXCR4 isoform b氨基端14個氨基酸肽段為免疫原，經(jīng)肽段親和柱純化，可識別人、小鼠、大鼠來源的CXCR4蛋白，并預(yù)測對牛(86%)和豬(71%)具有交叉反應(yīng)性?經(jīng)驗證可用于Western Blot、免疫組化(IHC-P)、免疫熒光(IF)、免疫細(xì)胞化學(xué)(ICC)、流式細(xì)胞術(shù)(FC)和ELISA等多種應(yīng)用，覆蓋從蛋白表達(dá)檢測到細(xì)胞定位分析的完整實驗需求?此外，該抗體通過了獨立抗體驗證、siRNA敲低驗證及重組蛋白檢測等多重特異性驗證，數(shù)據(jù)可靠，品質(zhì)值得信賴?

產(chǎn)品信息

實驗圖例

圖1. Western Blot Validation of CXCR4 in HeLa Cells

Loading: 15 ug of lysates per lane. Antibodies: 1009 (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

圖2. Immunofluorescence Validation of CXCR4 in HeLa Cells

Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling CXCR4 with 1009 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on HeLa cells.

圖3. Immunohistochemistry Validation of CXCR4 in Human Spleen

Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CXCR4 antibody (1009) at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A Goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

ProSci致力于為生命科學(xué)研究者提供高品質(zhì)?經(jīng)過嚴(yán)格驗證的抗體產(chǎn)品，以獨立抗體驗證和多維度特異性檢測為特色，為您的科研提供堅實可靠的數(shù)據(jù)支撐?

詳情請聯(lián)系ProSci中國代理商——欣博盛生物